A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease


Trial ID: NCT03131453


The purpose of this study is to determine the effects of CNP520 on cognition, global clinical status, and underlying AD pathology, as well as the safety of CNP520, in people at risk for the onset of clinical symptoms of AD based on their age, APOE genotype and elevated amyloid.

Official Title

A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of CNP520 in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease (AD).

Stanford Investigator(s)

Sharon Sha, MD, MS
Sharon Sha, MD, MS

Clinical Professor, Neurology & Neurological Sciences


Inclusion Criteria:

   - consent to receive disclosure of their risk estimates to develop clinical symptoms of
   AD based on their APOE genotype and, if Heterozygotes, evidence of elevated brain

   - Male or female, age 60 to 75 years inclusive. Females must be considered
   post-menopausal and not of child bearing potential

   - Cognitively unimpaired as evaluated by memory tests performed at screening.

   - Participant's willingness to have a study partner.

   - Carrier of at least one APOE4 gene if Heterozygotes, elevated brain amyloid (as
   measured by CSF Abeta or amyloid PET imaging).

Exclusion Criteria:

   - Any disability that could have prevented the participants from completing all study
   requirements. -

   - Current medical or neurological condition that could have impacted cognition or
   performance on cognitive assessments.

   - Advanced, severe progressive or unstable disease that could have interfered with the
   safety, tolerability and study assessments, or put the participant at special risk.

   - History of malignancy of any organ system, treated or untreated, within the past 60

   - Indication for, or current treatment with ChEIs and/or another AD treatment (e.g.

   - Contraindication or intolerance to MRI.

   - Brain MRI results showing findings unrelated to AD that, in the opinion of the
   Investigator might be a leading cause to future cognitive decline, could have posed a
   risk to the participant, or could have prevented a satisfactory MRI assessment for
   safety monitoring.

   - Suicidal Ideation in the past six months, or Suicidal Behavior in the past two years.

   - A positive drug screen at Screening, if, in the Investigator's opinion, was is due to
   drug abuse.

   - Significantly abnormal laboratory results at Screening, not as a result of a temporary

   - Current clinically significant ECG findings.

   - Clinically relevant depigmenting or hypopigmenting conditions (e.g. albinism,
   vitiligo) or active / history of chronic urticaria in the past year.


drug: CNP520 50mg

drug: CNP520 15mg

other: Matching placebo


Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305